Inclusion Criteria:

1. Adults ≥ 18 years of age at time of study vaccination.

2. Part 1: Previously vaccinated with ≥ 3 doses of the Moderna and/or Pfizer /BioNTech
prototype monovalent and/or BA.4/5 containing bivalent COVID-19 vaccines with the
last dose administered ≥ 90 days prior to study vaccination.

Part 2: Clinical history of COVID-19-like disease during the previous year.

3. Willing and able to give informed consent prior to study enrollment and to comply
with study procedures.

4. Female participants of childbearing potential (defined as any participant who has
experienced menarche and who is NOT surgically sterile [ie, hysterectomy, bilateral
tubal ligation, or bilateral oophorectomy] or postmenopausal [defined as amenorrhea
≥ 12 consecutive months]) must agree to be heterosexually in-active from at least 28
days prior to enrollment and through the end of the study OR agree to consistently
use a medically acceptable method of contraception listed below from ≥ 28 days prior
to enrollment and through the end of the study.

1. Condoms (male or female) with spermicide (if acceptable in country)

2. Diaphragm with spermicide

3. Cervical cap with spermicide

4. Intrauterine device

5. Oral or patch contraceptives

6. Norplant®, Depo-Provera®, or other in country regulatory approved contraceptive
method that is designed to protect against pregnancy.

7. Abstinence, as a form of contraception, is acceptable if in line with the
participant's lifestyle NOTE: Periodic abstinence (eg, calendar, ovulation,
sympto-thermal, post-ovulation methods) and withdrawal are not acceptable
methods of contraception.

5. Is medically stable, as determined by the investigator (based on review of health
status, vital signs [to include body temperature], medical history, and physical
examination [to include body weight]). Vital signs must be within medically
acceptable ranges prior to study vaccination.

6. Agrees to not participate in any research involving receipt of investigational
products (drug/biologic/device) including other SARS-CoV-2 prevention or treatment
trials for the duration of the study.

NOTE: For participants who become hospitalized with COVID-19, participation in
investigational treatment studies is permitted.

Exclusion Criteria:

1. Received COVID-19 vaccines other than Moderna and/or Pfizer-BioNTech in the past,
inclusive of clinical trial COVID-19 vaccines.

2. Participation in research involving receipt of investigational products
(drug/biologic/device) within 90 days prior to study vaccination (Day 0).

3. Received influenza vaccination within 14 days prior to study vaccination, or any
other vaccine within 30 days prior to study vaccination.

4. Any known allergies to products contained in the investigational product.

5. Any history of anaphylaxis to any prior vaccine.

6. Autoimmune or immunodeficiency disease/condition (iatrogenic or congenital)
requiring ongoing immunomodulatory therapy.

NOTE: Stable endocrine disorders (eg, thyroiditis, pancreatitis), including stable
diabetes mellitus with no history of diabetic ketoacidosis are NOT excluded.

7. Chronic administration (defined as > 14 continuous days) of immunosuppressant,
systemic glucocorti-coids, or other immune-modifying drugs within 90 days prior to
study vaccination (Day 0).

NOTE: An immunosuppressant dose of glucocorticoid is defined as a systemic dose ≥ 10
mg of prednisone per day or equivalent. The use of topical or intranasal
glucocorticoids is permitted. Topical tacrolimus and ocular cyclosporin are
permitted. Use of inhaled glucocorticoids is prohibited.

8. Received any prohibited medication (see Section 7.4.1), immunoglobulin,
blood-derived products, or immunosuppressant drugs within 90 days prior to study
vaccination (Day 0).

9. Active cancer (malignancy) on chemotherapy within 3 years prior to first study
vaccination (with the exception of adequately treated non-melanomatous skin
carcinoma or lentigo malign and uterine cervical carcinoma in situ without evidence
of disease, at the discretion of the investigator).

10. Participants who are breastfeeding, pregnant, or who plan to become pregnant prior
to the end of study.

11. Suspected or known history of alcohol abuse or drug addiction within 2 years prior
to study vaccination that, in the opinion of the investigator, might interfere with
protocol compliance.

12. Any other condition that, in the opinion of the investigator, would pose a health
risk to the participant if enrolled or could interfere with evaluation of the study
vaccine or interpretation of study results (includ-ing neurologic or psychiatric
conditions likely to impair the quality of safety reporting).

13. Study team member or immediate family member of any study team member (inclusive of
Sponsor, clinical research organization [CRO], and study site personnel involved in
the conduct or planning of the study).

14. Known history of myocarditis or pericarditis.

15. Respiratory symptoms in the past 3 days (ie, cough, sore throat, difficulty
breathing).

16. Temperature of > 38°C within 24 hours of planned study vaccination (site measured or
participant meas-ured).

17. Blood pressure of ≥ 160/100 mmHg.